Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
ARGX-119 in Amyotrophic Lateral Sclerosis: NCT06441682 Clinical Landscape Report 2026
15 October 2026
NCT06441682 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute) in Triple Negative Breast Cancer: NCT06435351 Clinical Landscape Report 2026
15 October 2026
NCT06435351 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
YL-202 in Triple Negative Breast Cancer: NCT06439771 Clinical Landscape Report 2026
15 October 2026
NCT06439771 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zirconium (89Zr) girentuximabum senvedoxamum in Renal Cell Carcinoma: NCT06447103 Clinical Landscape Report 2026
15 October 2026
NCT06447103 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ubamatamab in Sarcoma: NCT06444880 Clinical Landscape Report 2026
15 October 2026
NCT06444880 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VET3-TGI in Advanced Malignant Solid Neoplasm: NCT06444815 Clinical Landscape Report 2026
15 October 2026
NCT06444815 clinical landscape for Advanced Malignant Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
ZM-008 in Metastatic Renal Cell Carcinoma: NCT06451497 Clinical Landscape Report 2026
15 October 2026
NCT06451497 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RJK-002 in Amyotrophic Lateral Sclerosis: NCT06454682 Clinical Landscape Report 2026
15 October 2026
NCT06454682 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Eribulin mesylate in Locally advanced breast cancer: NCT06449222 Clinical Landscape Report 2026
15 October 2026
NCT06449222 clinical landscape for Locally advanced breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
D2C7-based immunotoxins(Istari Oncology, Inc.) in Glioblastoma, IDH-Wildtype: NCT06455605 Clinical Landscape Report 2026
15 October 2026
NCT06455605 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Siplizumab in Amyotrophic Lateral Sclerosis: NCT06453668 Clinical Landscape Report 2026
15 October 2026
NCT06453668 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ACT-50 in Metastatic Triple-Negative Breast Carcinoma: NCT06460298 Clinical Landscape Report 2026
15 October 2026
NCT06460298 clinical landscape for Metastatic Triple-Negative Breast Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…